-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Public Health and Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience powered by Apple
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Environmental Social Governance
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions powered by Apple
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm. IQVIA and Apple are collaborating to bring this exciting future of personalized care directly to devices patients already have and use.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSInstitute Report
Spotlight on Biosimilars
Optimising the Sustainability of Healthcare Systems
Jun 24, 2021
About the Report
The global biologic medicines market is a growing and increasingly important portion of pharmaceutical expenditure for countries and managing this becomes a necessary part of sustainable healthcare systems. The concept of ‘biosimilar sustainability’ has therefore become increasingly important for all stakeholders to understand. This report highlights examples of the benefits biosimilar competition can create as well as how these benefits can be unlocked through optimisation. In this report, the sustainability of the biosimilars marketplace was assessed across a set of five European countries with a broad spectrum of systems and approaches.
Report Summary
In this report, countries benefit from an independent view on the current system. To date, countries have made progress toward sustainable practises in many markets. However, our study of these markets revealed the following three themes as the most common hurdles to biosimilar sustainability: unsustainable purchasing policies for the procurement of biologics; limited tangible benefits offered to prescribers to encourage the use of biosimilars; and lack of physician and patient education on biosimilars. Although many of the best practice approaches that support biosimilar sustainability are already present somewhere in Europe, they are not consistently implemented in every country. As each country has a unique policy footprint and has started from different positions, the journey toward a sustainable market is different for each individual market. It is in the best interests of all stakeholders to learn from the issues that have arisen, gather perspectives from other countries, and implement targeted approaches for their individual markets that will work into the future to optimise the system and unlock the full benefits of biosimilars.
Key exhibits
Definition of ‘Biosimilar Sustainability’
- ‘Sustainability’ in a healthcare context is a journey in which, ideally, all stakeholders within a market can function effectively. It is the creation of a system that benefits all stakeholders, focussing on the patient, and ultimately ensures the longevity of a system.
- The concept of ‘biosimilar sustainability’ was advanced in 2018 as an approach to deliver on the promise of biosimilars. They can balance pharmaceutical spending, unlock savings for future innovation, and ultimately improve access to biologic therapies through competition.
- Experts - from policymakers to clinicians - agree with the definition and mention the necessity to emphasise the high quality of biosimilars and achievable savings, and often highlighting that authorities and payers are focused mostly on savings, with other factors (patient access, level of supply) being less of a priority.
- The long-term sustainability of a marketplace is an important concept to understand for all stakeholders in the healthcare system, given the increasing importance of biologics and of leveraging biosimilar competition.
Criteria for a sustainable market
- Reviewing the healthcare systems across the individual elements of the ‘Biosimilar Sustainability Assessment Framework’ shows areas that have a positive improvement or pose a potential risk to sustainability.
- By working closely with experts in each of the chosen countries and regions, we were able to highlight examples of sustainable practises within their systems. The report focuses on the positives, highlighting examples of best practise and policy hurdles using the framework below.
- Each country has a unique policy footprint and has started from different positions. The journey to a sustainable market is therefore different for each country, but using this approach highlights the common opportunities to optimise the system and unlock the benefits.
- A deep dive on these countries and regions is provided in the appendix of the report to provide some example of markets studied.
Herfindahl-Hirschman Index of Market Concentration (ordered by date of biosimilar entry)
- For the countries in scope, low levels of competition can often be a consequence of other issues rather than a cause. While historic perspectives on biosimilars have focussed on key performance indicators dedicated to uptake curves and market share, increasingly our approach has been updated to focus on ‘level of competition.’
- A comparative analysis using Sweden viewed single and multi-winner tenders and found that multiple-winner tenders may result in lower average net molecule costs per defined daily dose (DDD) for a region overall. Cost savings occur since price reductions are obtained on all contracted products (often including the originator) in multiple-winner tenders rather than only on one product in single-tender winner scenarios. Multi-winner tenders also keep multiple manufacturers actively engaged, commonly reduce prices of all winning brands, respect physician’s choice, and enable patient continuation on current treatment.
- In a sustainable market, originators can continue to play a role alongside biosimilars. However, originators may have high market share due to several non-sustainable reasons: reluctance of HCPs (lacking education, awareness or clear evidence for biosimilars safety and quality), key opinion leaders sticking to originators in some regions, novel route of administration introduced, or simply due to high competition in some regions with high volumes available.
- Those with unsustainable practises will not be able to achieve long-term savings through continued competition.